|Awarded On||February 18, 2015|
|Title||Targeting 17q23 amplicon in HER2-positive Breast Cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Xinna Zhang|
In about 1 of every 5 breast cancers, the cancer cells make an excess of HER2 (human epidermal growth factor receptor 2) due to the gene amplification and overexpression. HER2-positive breast cancers tend to be more aggressive than other types of breast cancer. They are also less responsive to hormone treatment. The HER2 antibody trastuzumab and the tyrosine kinase inhibitor lapatinib are currently the two FDA-approved drugs for the treatment of HER2-positive breast cancer. Although clinically effective, many patients with HER2-positive breast cancer either do not respond or eventually develop resistance to trastuzumab and lapatinib, suggesting the presence of de novo and acquired mechanisms...